Logo

Rosetta Genomics, GeneKor Expand Distribution Agreement

Nov 20, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that its distribution agreement with GeneKor Medical has been expanded to include Romania and Turkey.

GeneKor now has the exclusive sales and marketing rights to Rosetta Genomics' microRNA-based cancer testing services in Romania, and non-exclusive rights in Turkey. The companies originally inked a distribution deal covering Greece in 2010.

Financial and other terms of today's deal were not disclosed.

GeneKor is a molecular diagnostic service provider headquartered in Athens, Greece.

"This extension to our agreement with GeneKor will enhance patient access to our microRNA-based testing services in Turkey and Romania, and will potentially result in more personalized treatment approaches for many patients," E. Robert Wassman, chief medical officer of Rosetta Genomics, said in a statement.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Diagnostics
Cancer
Business News
distribution agreement
RNAi
miRNA
Rosetta Genomics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.